ENSC · Ensysce Biosciences, Inc.
$0.50
0.00 (-0.60%)
At close · Oct 21
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These matters, among others, raise substantial doubt about the Company's ability to continue as a going concern. While the Company believes in the viability of its strategy to ultimately realize revenues and in its ability to raise additional funds, management cannot be certain that additional funding will be available on acceptable terms, or at all. The Company's ability to continue as a going concern is dependent upon its ability to obtain adequate financing and achieve profitable operations. As a result, these plans do not alleviate substantial doubt about the Company's ability to continue as a going concern for a period of 12 months following the date these consolidated financial statements were issued.”View the 10-Q filed Aug 13, 2026
Market Cap
$9.70M
Shares
19.46M
Volume · Oct 21
138.01K
Avg daily vol (3M)
13.76M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.50
Open$0.55
Day$0.50–0.55
52W close$0.25–2.55
Avg vol 30d549K
Short int1.1M · 5.6% float · 3.4d
Short vol14%
Last earningsAug 18, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 13
Up next
Next earnings call
Jun 5, 2027
Est · unconfirmed
· in 32 wks
filed Aug 13, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$4.50M
Trailing 12 months
Net income (TTM)
−$12.62M
Trailing 12 months
Revenue growth YoY
-15.1%
Year over year
Operating margin
-281.3%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$479,862
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+491.9%
Year over year · more shares
Price change (1Y)
-80.4%
Trailing year
Short interest
5.6%
Latest settlement · 3.4 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Strong
Sentiment
Bullish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 17.3 · elevated
Equity put/call 0.56
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+10%
above
Price vs 50-day avg
+13%
above
RSI (14)
54
neutral
MACD trend
Positive
52-week position
11%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+16%
trailing
6-month return
+38%
trailing
YTD return
−46%
this year
Relative strength
+30%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Flat
1 of 18 funds reported for Sep 30 · net 0 sh shares
Insider flow
Accumulating
Net +$198.0K over 90 days · 0% sells
Short interest
Falling
5.56% of float · ▼ -10.4% MoM · 3.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
18 holders — near 3-yr high, broad support
Squeeze score
60
elevated · 0–100
Fundamentals
Revenue growth
−3%
Y/Y
EPS growth
+65%
Y/Y
Free cash flow
$-7.9M
Balance sheet
$4.0M
net cash
Quant / Vol
risk profile
Volatility
136%
annualized · 1-yr
Max drawdown
−90%
past year
ATR
9.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+10%
Bullish
Price vs 50-day avg
+13%
Bullish
RSI (14)
54
Neutral
MACD trend
Positive
Bullish
52-week position
11%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Flat
1 of 18 funds reported for Sep 30 · net 0 sh shares
Insider flow
Accumulating
Net +$198.0K over 90 days · 0% sells
Short interest
Falling
5.56% of float · ▼ -10.4% MoM · 3.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
18 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $0
Now $0 · 11%
Range high $3
vs 200-day avg +10%
vs 50-day avg +13%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ENSC
this stock
Ensysce Biosciences, Inc.
|
$9.70M | -45.8% | -2.8% | — | 5.6% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.07B | +13.5% | +46.2% | 29.9 | 1.8% |
|
MRNA
Moderna, Inc.
|
$96.65B | +720.9% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$83.13B | +4.6% | +20.8% | 20.0 | 2.1% |
|
CSLLY
Csl Ltd
|
$66.34B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
SEC Filings
Latest
8-K/A
- Filed
- Oct 16, 2026
- This year
- 22
Ensysce Biosciences filed an Amendment No. 2 to its August 6, 2026 8-K to add risk factors, a business overview, historical financials of Cy Biopharma, and unaudited pro forma combined financial statements for the six months ended June 30, 2026 and the year ended December 31, 2025.
ViewEarnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ENSC | -12.9% | +16.2% | +38.1% | +19.9% | -45.8% |
| SPY | -1.2% | -0.6% | +8.1% | +0.8% | +12.8% |
| vs SPY | -11.8% | +16.8% | +30.0% | +19.1% | -58.6% |